Literature DB >> 19053961

Delayed neovascularization in inflammation-induced corneal neovascularization in interleukin-10-deficient mice.

Branka Samolov1, Anders Kvanta, Ingeborg van der Ploeg.   

Abstract

PURPOSE: To investigate the potential modulatory role of interleukin-10 (IL-10) in the suture model for corneal neovascularization.
METHODS: Neovascularized areas were measured on corneal flat-mounts in IL-10(-/-) and wild-type C57BL6 mice. The inflammatory cellular response was characterized with immunohistochemistry. Gene expression was measured by real-time polymerase chain reaction.
RESULTS: IL-10(-/-) mice showed a delayed neovascular response compared to wild-type animals at day 6 after suture, when approximately half of the cornea was neovascularized. No apparent differences in inflammatory responses or in messenger RNA (mRNA) expression for proangiogenic factors were detected in IL-10(-/-) versus wild-type mice.
CONCLUSION: IL-10 appears to have a proangiogenic effect in the suture model for corneal neovascularization that cannot be explained by either IL-10's anti-inflammatory effect or apparent cross-talk with the angiogenic factors vascular endothelial growth factor (VEGF)-A, metalloproteinase (MMP)-2 and MMP-9, angiopoietin (Ang)-1 and Ang-2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19053961     DOI: 10.1111/j.1755-3768.2008.01393.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  2 in total

1.  Nona-D-arginine amide suppresses corneal cytokines in Pseudomonas aeruginosa keratitis.

Authors:  Priyanka Karicherla; Siddhesh Aras; Ashok Aiyar; Jeffery A Hobden
Journal:  Cornea       Date:  2010-11       Impact factor: 2.651

2.  Delivery of silver sulfadiazine and adipose derived stem cells using fibrin hydrogel improves infected burn wound regeneration.

Authors:  Jaideep Banerjee; Shanmuganathan Seetharaman; Nicole L Wrice; Robert J Christy; Shanmugasundaram Natesan
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.